• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

作者信息

Brahmer Julie R, Lacchetti Christina, Thompson John A

机构信息

Johns Hopkins Kimmel Cancer Center, Baltimore, MD; American Society of Clinical Oncology, Alexandria, VA; University of Washington; and Fred Hutchinson Cancer Research Center, Seattle, WA.

出版信息

J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.

DOI:10.1200/JOP.18.00005
PMID:29517954
Abstract
摘要

相似文献

1
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.接受免疫检查点抑制剂治疗患者免疫相关不良事件的管理：美国临床肿瘤学会临床实践指南摘要
J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.
2
Management of Immunotherapy-Related Toxicities, Version 1.2019.免疫治疗相关毒性的管理，版本 1.2019.
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.
3
Challenging Cases: Management of Immune-Related Toxicity.疑难病例：免疫相关毒性的管理
Am Soc Clin Oncol Educ Book. 2018 May 23;38:179-183. doi: 10.1200/EDBK_209557.
4
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.一项关于免疫相关不良反应的发生与晚期癌症患者接受检查点抑制剂治疗的临床结局之间新出现关联的系统评价。
Semin Oncol. 2019 Aug-Oct;46(4-5):362-371. doi: 10.1053/j.seminoncol.2019.10.003. Epub 2019 Nov 7.
5
Equibalancing immune-related adverse events and anticancer activity of immune checkpoint inhibitors.平衡免疫检查点抑制剂的免疫相关不良事件和抗癌活性。
Thorac Cancer. 2019 Oct;10(10):1855-1856. doi: 10.1111/1759-7714.13180. Epub 2019 Aug 28.
6
Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.免疫检查点抑制剂相关的具有挑战性的免疫相关胃肠道不良事件的管理。
Future Oncol. 2018 Dec;14(30):3187-3198. doi: 10.2217/fon-2018-0509. Epub 2018 Sep 6.
7
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
8
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).SEOM 临床指南：免疫检查点抑制剂治疗患者免疫相关不良事件的管理（2019 年）。
Clin Transl Oncol. 2020 Feb;22(2):213-222. doi: 10.1007/s12094-019-02273-x. Epub 2020 Jan 28.
9
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.NCCN 指南更新：免疫治疗相关毒性的识别与管理。
J Natl Compr Canc Netw. 2018 May;16(5S):594-596. doi: 10.6004/jnccn.2018.0047.
10
Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.与癌症免疫检查点抑制剂使用相关的自身免疫性溶血性贫血：来自美国食品和药物管理局数据库的 68 例病例和综述。
Eur J Haematol. 2019 Feb;102(2):157-162. doi: 10.1111/ejh.13187. Epub 2018 Nov 29.

引用本文的文献

1
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury.类固醇难治性免疫检查点抑制剂诱导的肝损伤的机制研究与治疗进展
Clin Exp Med. 2025 Aug 11;25(1):288. doi: 10.1007/s10238-025-01721-z.
2
Rapid Onset of Fulminant Type 1 Diabetes 10 Days After the First Dose of Nivolumab: A Case Report.首次使用纳武单抗10天后暴发性1型糖尿病快速发病：一例报告
Cureus. 2025 Jun 13;17(6):e85957. doi: 10.7759/cureus.85957. eCollection 2025 Jun.
3
Immunotherapy related endocrinopathy of the pineal and pituitary gland that resolved following discontinuation of treatment: case report.
免疫治疗相关的松果体和垂体内分泌病，停药后病情缓解：病例报告
Neuroradiology. 2025 Jul 8. doi: 10.1007/s00234-025-03687-x.
4
Pembrolizumab-Induced Hypophysitis: A Rare Immune-Related Adverse Event in a Patient With Metastatic Non-small Cell Lung Cancer.帕博利珠单抗诱发的垂体炎：一名转移性非小细胞肺癌患者罕见的免疫相关不良事件
Cureus. 2025 Apr 21;17(4):e82701. doi: 10.7759/cureus.82701. eCollection 2025 Apr.
5
Immune-related adverse events-pembrolizumab-induced colitis-the importance of early diagnosis and treatment: A case report and review of the literature.免疫相关不良事件——帕博利珠单抗诱发的结肠炎——早期诊断和治疗的重要性：一例病例报告及文献综述
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251326699. doi: 10.1177/03946320251326699. Epub 2025 Apr 15.
6
Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review.抗肿瘤药物继发口腔并发症的处理——综述
Cancers (Basel). 2025 Mar 21;17(7):1061. doi: 10.3390/cancers17071061.
7
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis.一名患有乳头状肾细胞癌和免疫相关性重症肌无力的患者在接受大剂量类固醇干预后肿瘤对免疫肿瘤治疗的反应
Cureus. 2025 Mar 6;17(3):e80136. doi: 10.7759/cureus.80136. eCollection 2025 Mar.
8
Early Prediction of Pembrolizumab-Induced Hypothyroidism Based on the Neutrophil-to-Lymphocyte Ratio.基于中性粒细胞与淋巴细胞比值对帕博利珠单抗所致甲状腺功能减退的早期预测
Cureus. 2025 Mar 4;17(3):e80049. doi: 10.7759/cureus.80049. eCollection 2025 Mar.
9
Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis.免疫检查点抑制剂诱发肺炎患者的长期预后
BMJ Open Respir Res. 2023 Apr 6;10(1):e001342. doi: 10.1136/bmjresp-2022-001342.
10
Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management.免疫检查点抑制剂诱发的肝炎：一例具有挑战性治疗的病例报告
Cureus. 2025 Jan 12;17(1):e77331. doi: 10.7759/cureus.77331. eCollection 2025 Jan.